Teladoc Health, Inc. (NYSE:TDOC) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP lessened its stake in shares of Teladoc Health, Inc. (NYSE:TDOC - Free Report) by 52.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 112,806 shares of the health services provider's stock after selling 123,580 shares during the quarter. Bridgewater Associates LP owned about 0.07% of Teladoc Health worth $1,036,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Signaturefd LLC lifted its holdings in Teladoc Health by 148.7% in the 2nd quarter. Signaturefd LLC now owns 2,868 shares of the health services provider's stock valued at $28,000 after purchasing an additional 1,715 shares in the last quarter. International Assets Investment Management LLC acquired a new position in Teladoc Health during the second quarter worth approximately $29,000. Blue Trust Inc. raised its position in shares of Teladoc Health by 84.5% in the 3rd quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider's stock worth $40,000 after buying an additional 1,854 shares during the period. Doheny Asset Management CA purchased a new stake in Teladoc Health during the second quarter valued at about $46,000. Finally, Benjamin F. Edwards & Company Inc. grew its holdings in shares of Teladoc Health by 209.8% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 5,015 shares of the health services provider's stock worth $49,000 after purchasing an additional 3,396 shares during the period. Institutional investors and hedge funds own 76.82% of the company's stock.

Teladoc Health Stock Performance

Shares of NYSE:TDOC traded down $0.47 during trading on Monday, reaching $11.51. 7,480,330 shares of the company's stock traded hands, compared to its average volume of 5,572,900. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.73 and a quick ratio of 1.69. The company has a 50 day moving average of $9.38 and a 200-day moving average of $9.23. The stock has a market capitalization of $1.98 billion, a P/E ratio of -2.10 and a beta of 0.90. Teladoc Health, Inc. has a 12 month low of $6.76 and a 12 month high of $22.54.

Teladoc Health (NYSE:TDOC - Get Free Report) last posted its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.10. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. The firm had revenue of $640.51 million during the quarter, compared to analyst estimates of $630.50 million. On average, equities analysts expect that Teladoc Health, Inc. will post -1.16 EPS for the current year.

Insiders Place Their Bets

In other news, Director Thomas Mckinley bought 4,000 shares of the company's stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average price of $7.69 per share, with a total value of $30,760.00. Following the completion of the acquisition, the director now directly owns 39,077 shares in the company, valued at approximately $300,502.13. This trade represents a 11.40 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Willem Waters sold 4,218 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total value of $30,200.88. Following the transaction, the chief operating officer now directly owns 78,309 shares of the company's stock, valued at approximately $560,692.44. The trade was a 5.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,051 shares of company stock worth $143,565. 0.95% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Evercore ISI lifted their target price on shares of Teladoc Health from $8.00 to $9.00 and gave the company an "in-line" rating in a report on Tuesday, October 8th. Royal Bank of Canada upped their target price on Teladoc Health from $9.00 to $10.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $10.00 target price on shares of Teladoc Health in a report on Tuesday, August 20th. Barclays boosted their price target on Teladoc Health from $10.00 to $12.00 and gave the stock an "overweight" rating in a research report on Thursday, October 31st. Finally, Piper Sandler dropped their price objective on shares of Teladoc Health from $25.00 to $10.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. Fourteen research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $12.08.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.